NGL FINECHEM
Back to Balance Sheet
|
NGL FINECHEM Last 5 Year Contingent Liabilities History
[Consolidated]
Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
---|---|---|---|---|---|
Contingent Liabilities | ₹0.44 Cr | ₹0.10 Cr | ₹0.28 Cr | ₹0.28 Cr | ₹0.30 Cr |
What is the latest Contingent Liabilities ratio of NGL FINECHEM ?
Year | Contingent Liabilities |
---|---|
Mar2024 | ₹0.44 Cr |
Mar2023 | ₹0.10 Cr |
Mar2022 | ₹0.28 Cr |
Mar2021 | ₹0.28 Cr |
Mar2020 | ₹0.30 Cr |
How is Contingent Liabilities of NGL FINECHEM Trending?
Years | Contingent Liabilities | % Change | |
---|---|---|---|
Mar2024 | ₹0.44 Cr | 336.63 | |
Mar2023 | ₹0.10 Cr | -63.67 | |
Mar2022 | ₹0.28 Cr | 0.00 | |
Mar2021 | ₹0.28 Cr | -6.40 | |
Mar2020 | ₹0.30 Cr | - |
Compare Contingent Liabilities of peers of NGL FINECHEM
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
NGL FINECHEM | ₹1,078.2 Cr | 1.7% | -3.4% | -14.9% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹416,692.0 Cr | -5.3% | -7.8% | 24.1% | Stock Analytics | |
DIVIS LABORATORIES | ₹149,215.0 Cr | -3.9% | -7.9% | 51% | Stock Analytics | |
CIPLA | ₹115,000.0 Cr | -1.9% | -6.9% | 3.6% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹98,616.4 Cr | -8.3% | -14.9% | 0.8% | Stock Analytics | |
ZYDUS LIFESCIENCES | ₹93,841.4 Cr | -5.7% | -4% | 23.6% | Stock Analytics |
NGL FINECHEM Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
NGL FINECHEM | 1.7% |
-3.4% |
-14.9% |
SENSEX | 0.2% |
-2.2% |
7.7% |
You may also like the below Video Courses